Publication details
Dlouhodobá bezpečnost adalimumabu a nové indikace pro dermatologii
| Title in English | Adalimumab - long-term safety and new indications in dermatology |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Dermatologie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Dermatovenerology |
| Keywords | adalimumab; safety; palmoplantar psoriasis |
| Description | Adalimumab is a recombinant human monoclonal antibody against tumour necrosis factor alfa (TNF-alfa). It is indicated for the treatment of moderate to severe chronic plaque psoriasis in adults in whom other systemic treatment is not efficacious or it is contraindicated or not tolerated. Now, based on REACH study, adalimumab is also indicated in the treatment of moderate to severe chronic plaque psoriasis of hands and/or feet. REACH study proved that treatment with adalimumab resulted in better quality of life because of reduced pain and nail improvement. Adalimumab is efficacious and safe drug for a long-term treatment of chronic plaque psoriasis. |